179 related articles for article (PubMed ID: 22422502)
1. Sequential design of phase II-III cancer trials.
Lai TL; Lavori PW; Shih MC
Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
[TBL] [Abstract][Full Text] [Related]
2. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
4. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
5. Seamlessly expanding a randomized phase II trial to phase III.
Inoue LY; Thall PF; Berry DA
Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
[TBL] [Abstract][Full Text] [Related]
6. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Rufibach K; Heinzmann D; Monnet A
Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
[TBL] [Abstract][Full Text] [Related]
7. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
8. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
Kimani PK; Todd S; Stallard N
Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
[TBL] [Abstract][Full Text] [Related]
9. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
10. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
11. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
12. Adaptive seamless designs with interim treatment selection: a case study in oncology.
Carreras M; Gutjahr G; Brannath W
Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
[TBL] [Abstract][Full Text] [Related]
13. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
14. Play the winner for phase II/III clinical trials.
Yao Q; Wei LJ
Stat Med; 1996 Nov 15-30; 15(21-22):2413-23; discussion 2455-8. PubMed ID: 8931210
[TBL] [Abstract][Full Text] [Related]
15. Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.
Stallard N; Kunz CU; Todd S; Parsons N; Friede T
Stat Med; 2015 Oct; 34(23):3104-15. PubMed ID: 26112909
[TBL] [Abstract][Full Text] [Related]
16. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
17. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
18. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different clinical development plans for confirmatory subpopulation selection.
Rufibach K; Chen M; Nguyen H
Contemp Clin Trials; 2016 Mar; 47():78-84. PubMed ID: 26744231
[TBL] [Abstract][Full Text] [Related]
20. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
